Unbound MEDLINE

Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial.

Abstract

OBJECTIVE
To determine the effects of low-dose prolonged methylprednisolone infusion on lung function in patients with early severe ARDS.
DESIGN
Randomized, double-blind, placebo-controlled trial.
SETTING
ICUs of five hospitals in Memphis.
PARTICIPANTS
Ninety-one patients with severe early ARDS (</= 72 h), 66% with sepsis.
INTERVENTIONS
Patients were randomized (2:1 fashion) to methylprednisolone infusion (1 mg/kg/d) vs placebo. The duration of treatment was up to 28 days. Infection surveillance and avoidance of paralysis were integral components of the protocol.
MAIN OUTCOME MEASURE
The predefined primary end point was a 1-point reduction in lung injury score (LIS) or successful extubation by day 7.
RESULTS
In intention-to-treat analysis, the response of the two groups (63 treated and 28 control) clearly diverged by day 7, with twice the proportion of treated patients achieving a 1-point reduction in LIS (69.8% vs 35.7%; p = 0.002) and breathing without assistance (53.9% vs 25.0%; p = 0.01). Treated patients had significant reduction in C-reactive protein levels, and by day 7 had lower LIS and multiple organ dysfunction syndrome scores. Treatment was associated with a reduction in the duration of mechanical ventilation (p = 0.002), ICU stay (p = 0.007), and ICU mortality (20.6% vs 42.9%; p = 0.03). Treated patients had a lower rate of infections (p = 0.0002), and infection surveillance identified 56% of nosocomial infections in patients without fever.
CONCLUSIONS
Methylprednisolone-induced down-regulation of systemic inflammation was associated with significant improvement in pulmonary and extrapulmonary organ dysfunction and reduction in duration of mechanical ventilation and ICU length of stay.

Links

  • Publisher Full Text
  • Authors

    Meduri GU, Golden E, Freire AX, Taylor E, Zaman M, Carson SJ, Gibson M, Umberger R

    Institution

    Division of Pulmonary, Critical Care, and Sleep Medicine, University of Tennessee Health Science Center, 956 Court Ave, Room H316, Memphis, TN 38163, USA. umeduri@utmem.edu

    Source

    Chest 131:4 2007 Apr pg 954-63

    MeSH

    C-Reactive Protein
    Catecholamines
    Dose-Response Relationship, Drug
    Female
    Fluorescence Polarization Immunoassay
    Follow-Up Studies
    Glucocorticoids
    Hospital Mortality
    Humans
    Hydrocortisone
    Infusions, Intravenous
    Length of Stay
    Male
    Methylprednisolone
    Middle Aged
    Respiration, Artificial
    Respiratory Care Units
    Respiratory Distress Syndrome, Adult
    Retrospective Studies
    Time Factors
    Treatment Outcome

    Pub Type(s)

    Journal Article
    Multicenter Study
    Randomized Controlled Trial
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    17426195